Diaceutics PLC Total Assets
Diaceutics PLC total assets. Based on the latest financial reports, Diaceutics PLC (DXRX) holds total assets worth GBX50.01 Million GBX (≈ $6.08K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Diaceutics PLC market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Diaceutics PLC (2015–2025)
Total assets of Diaceutics PLC from 2015 to 2025. This chart illustrates how Diaceutics PLC's total assets have evolved over time, based on quarterly financial data. See DXRX stock price for real-time trading data and today's change.
Diaceutics PLC - Asset Composition Analysis
Diaceutics PLC Total Assets Breakdown (December 2025)
Diaceutics PLC total assets breakdown as of December 2025. Diaceutics PLC's total assets of GBX50.01 Million consist of 58.7% current assets and 41.3% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 14.7% |
| Accounts Receivable | GBX20.97 Million | 41.9% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX16.08 Million | 32.2% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Diaceutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Diaceutics PLC to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Diaceutics PLC's current assets represent 58.7% of total assets in 2025, a decrease from 98.7% in 2015.
- Cash Position: Cash and equivalents constituted 14.7% of total assets in 2025, up from 9.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 32.0% of total assets, an increase from 1.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 41.9% of total assets.
Diaceutics PLC Competitors by Total Assets
Key competitors of Diaceutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Imexhs Ltd
AU:IME
|
Australia | AU$22.81 Million |
|
LifeMD Inc
NASDAQ:LFMD
|
USA | $70.41 Million |
|
Veeva Systems Inc Class A
NYSE:VEEV
|
USA | $9.13 Billion |
|
Carespan Health Inc
V:CSPN
|
Canada | CA$116.81K |
|
Heartbeam Inc
NASDAQ:BEAT
|
USA | $10.64 Million |
|
Zhongchao Inc
NASDAQ:ZCMD
|
USA | $26.31 Million |
|
UNIDOC HEALTH CORP.
F:L7T
|
Germany | €2.30 Million |
|
Comprehensive Healthcare Systems Inc
V:CHS
|
Canada | CA$885.15K |
Diaceutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.43 | 3.80 | 11.53 |
| Quick Ratio | 3.43 | 3.80 | 11.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX20.81 Million | GBX21.76 Million | GBX30.70 Million |
Diaceutics PLC - Advanced Valuation Insights
This section examines the relationship between Diaceutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.11 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 2.9% |
| Total Assets | GBX50.01 Million |
| Market Capitalization | $2.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Diaceutics PLC's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Diaceutics PLC's assets grew by 2.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Diaceutics PLC (2015–2025)
The table below shows the annual total assets of Diaceutics PLC from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | GBX50.01 Million ≈ $6.08K |
+2.85% |
| 2024-12-31 | GBX48.62 Million ≈ $5.92K |
+4.91% |
| 2023-12-31 | GBX46.34 Million ≈ $5.64K |
-3.96% |
| 2022-12-31 | GBX48.26 Million ≈ $5.87K |
+7.20% |
| 2021-12-31 | GBX45.01 Million ≈ $5.48K |
+3.43% |
| 2020-12-31 | GBX43.52 Million ≈ $5.30K |
+94.53% |
| 2019-12-31 | GBX22.37 Million ≈ $2.72K |
+186.43% |
| 2018-12-31 | GBX7.81 Million ≈ $950.30 |
+42.23% |
| 2017-12-31 | GBX5.49 Million ≈ $668.16 |
+59.61% |
| 2016-12-31 | GBX3.44 Million ≈ $418.61 |
+156.49% |
| 2015-12-31 | GBX1.34 Million ≈ $163.21 |
-- |
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that en… Read more